Catalog No.
Product Name
Application
Product Information
Citations
-
Anti-inflammatory Agent
Kamebakaurin is an orally active diterpenoid that functions as an anti-inflammatory agent by inhibiting NF-κB activation through direct interference with the DNA-binding activity of p50. This compound exhibits significant biological activity, including the induction of apoptosis and cell cycle arrest in tumor cells. Kamebakaurin is relevant for research applications focused on inflammation and cancer therapeutics. -
NF-κB Agonist
Berubicin is an NF-κB agonist that serves as a doxorubicin analog with the ability to cross the blood-brain barrier. It effectively inhibits P-glycoprotein and MRP1-mediated efflux, demonstrating significant cytotoxicity against glioblastoma multiforme (GBM) and promoting apoptosis in neuroblastoma cells. Berubicin is valuable for investigating tumors of the nervous system and understanding the role of NF-κB in cancer progression. -
Iron Chelator
DpC is a selective iron chelator with significant anticancer properties. It targets key signaling pathways, including JNK and NF-κB, inducing oxidative stress in tumor cells through the formation of redox-active iron and copper complexes. DpC promotes apoptosis by activating caspase 3 and 9 and enhances immune responses by increasing TNF-α levels in the tumor microenvironment. Additionally, it effectively overcomes P-glycoprotein-mediated multidrug resistance and demonstrates broad synergistic effects with various chemotherapeutic agents. This compound is relevant for research into multiple malignancies, such as neuroblastoma, pancreatic, prostate, lung, and breast cancers. -
Anti-cancer Agent
Inotodiol is an anti-cancer agent that activates the p53 signaling pathway while inhibiting matrix metalloproteinases MMP-2 and MMP-9, demonstrating significant antitumor activity in HeLa cancer cells. Additionally, Inotodiol exhibits antioxidant and neuroprotective effects by reducing reactive oxygen species (ROS) generation. It also suppresses MAPK and NF-κB signaling pathways, showcasing anti-inflammatory properties. Inotodiol effectively inhibits TLR-4 mediated TNF-α production, with IC50 values of 0.7 μM and 3.0 μM in bone marrow-derived mast cells (BMMC) and macrophages (BMDM) respectively, while also reducing degranulation in mast cells, indicating potential applications in anti-allergic research. This compound is orally active. -
Stable Isotope
Aspirin-d4 is a deuterium-labeled form of Aspirin (Acetylsalicylic acid), functioning as a stable isotope for various biochemical applications. It acts as a potent and irreversible inhibitor of cyclooxygenase enzymes COX-1 and COX-2, demonstrating IC50 values of 5 and 210 μg/mL, respectively. Aspirin-d4 triggers apoptosis and inhibits NF-κB activation, while also affecting platelet function through the inhibition of prostaglandin synthetase. This reagent is suitable for studies involving inflammation, cardiovascular research, and cellular signaling pathways. -
TNFα inhibitor
Aloeresin G is a chromone glycoside derived from Aloe, demonstrating inhibitory activity against TNFα. It attenuates TNFα-induced NF-κB transcriptional activity, exhibiting an IC50 value of 40.02 μM. This compound is valuable for research focused on inflammatory pathways and the modulation of immune responses. -
Slow-releasing H2S Donor
FW1256 is a phenyl analogue and a slow-releasing hydrogen sulfide (H2S) donor. This compound inhibits NF-κB activity, leading to the induction of apoptosis in various cell types. FW1256 demonstrates significant anti-inflammatory properties and shows promise for applications in the treatment of cancer and cardiovascular diseases. -
HDAC/JAK/BRD4 Inhibitor
HDAC/JAK/BRD4-IN-1 is a potent inhibitor targeting histone deacetylases (HDAC), Janus kinases (JAK), and bromodomain-containing protein 4 (BRD4). This compound demonstrates significant anti-proliferative effects and promotes apoptosis in MDA-MB-231 breast cancer cells. Additionally, HDAC/JAK/BRD4-IN-1 exhibits promising anticancer activity in vivo, making it a valuable tool for research in cancer therapeutics and the study of epigenetic and signaling pathways. -
Stable Isotope
Sodium propionate-d5, a deuterated form of sodium propionate, primarily acts as a stable isotope label in metabolic studies. This short-chain fatty acid is produced by intestinal bacteria through dietary fiber metabolism and enhances PPAR-γ, while inhibiting NF-κB activation, COX-2 expression, and nitric oxide production. Sodium propionate-d5 displays biological activities such as inducing apoptosis and autophagy, along with potential neuroprotective, antioxidant, and anti-inflammatory effects. It serves as a valuable tool for investigating conditions such as spinal cord injury, Alzheimer's disease, and glioblastoma. -
Autophagy Inducer
Sanguinarine is a benzophenanthridine alkaloid that acts as an autophagy inducer. It is derived from the root of Sanguinaria canadensis and can stimulate apoptosis through the production of reactive oxygen species (ROS). The pro-apoptotic effects of sanguinarine are linked to the activation of the JNK and NF-κB signaling pathways, making it a valuable tool for research in cancer biology and cellular stress responses. -
HDAC1-3 Inhibitor
HDAC-IN-53 is a selective inhibitor of histone deacetylases 1-3, demonstrating IC50 values of 47 nM, 125 nM, and 450 nM for HDAC1, HDAC2, and HDAC3, respectively. This compound exhibits minimal off-target effects, as it does not inhibit class II HDACs (IC50 > 10 μM). HDAC-IN-53 promotes caspase-dependent apoptosis and has been shown to inhibit the growth of human tumor xenografts in nude mice, as well as murine tumors in immune-competent mice bearing MC38 colon cancer. It serves as a valuable tool for studying cancer biology and potential therapeutic strategies targeting HDAC pathways. -
HDAC6 Inhibitor
QTX125 TFA is a potent and highly selective inhibitor of Histone Deacetylase 6 (HDAC6). This compound demonstrates exceptional selectivity for HDAC6 over other isoforms, making it a valuable tool for studying the role of HDAC6 in various biological processes. QTX125 TFA has shown promising antitumor effects, indicating its potential for use in cancer research and therapeutic applications targeting HDAC6-related pathways. -
HDAC Inhibitor
CRA-026440 hydrochloride is a potent, broad-spectrum histone deacetylase (HDAC) inhibitor, exhibiting Ki values against recombinant HDAC isoenzymes of 4 nM for HDAC1, 14 nM for HDAC2, 11 nM for HDAC3, 15 nM for HDAC6, 7 nM for HDAC8, and 20 nM for HDAC10. This compound demonstrates significant antitumor and antiangiogenic activities, making it relevant for studies in cancer biology. Additionally, CRA-026440 hydrochloride possesses an alkyne functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), facilitating its use in click chemistry applications for bioconjugation studies. -
NF-κB Inhibitor
2′-Hydroxychalcone is a hydroxyl derivative of chalcones that primarily inhibits the NF-κB signaling pathway. It has demonstrated significant anticancer activity, inducing autophagy and apoptosis specifically in breast cancer cells. Additionally, 2′-Hydroxychalcone exhibits enhanced antifungal properties against Paracoccidioides spp., making it a valuable reagent for cancer and fungal research applications. -
Stable Isotope
Sodium propionate-d3 is a deuterium-labeled form of sodium propionate, a short-chain fatty acid that functions as a stable isotope. It selectively enhances PPAR-γ activation while inhibiting NF-κB activation, reducing COX-2 expression and nitric oxide production. This compound exhibits significant biological activities, including apoptosis induction and autophagy promotion, along with neuroprotective, antioxidant, and anti-inflammatory properties. Sodium propionate-d3 is valuable in research applications related to spinal cord injury, Alzheimer's disease, and the treatment of glioblastoma, as well as in studying viral infections such as HSV-1-induced keratitis. -
NF-κB Inhibitor/Nrf2/AMPK Activator
Panduratin A is a potent inhibitor of the NF-κB signaling pathway, recognized for its significant anti-inflammatory and antioxidant properties. It demonstrates protective effects against nephrotoxicity induced by Colistin, primarily by mitigating oxidative stress and enhancing mitochondrial function. Additionally, Panduratin A activates autophagy through an AMPK-dependent mechanism and exhibits potential anti-tuberculosis and antiviral activities by inhibiting the methyltransferase of SARS-CoV-2. These diverse biological activities make Panduratin A a valuable tool in various areas of research, including inflammation, cellular stress responses, and infectious diseases. -
Stable Isotope
Laquinimod-d5 is a deuterium-labeled variant of Laquinimod, a potent immunomodulator primarily targeting neuroinflammation in the central nervous system. This compound effectively reduces astrocytic NF-κB activation, offering protection against demyelination induced by Cuprizone. Laquinimod-d5 is intended for research applications exploring relapsing-remitting and chronic progressive forms of multiple sclerosis, as well as various neurodegenerative diseases. -
Molecular probe
AMC-01 is a molecular probe that specifically regulates the activity of eIF2-α. It induces the activation of protein kinase RNA-activated (PKR) and enhances nuclear factor κB (NF-κB) signaling. Additionally, AMC-01 functions to inhibit apoptosis, making it a valuable tool for investigating cellular stress responses and signaling pathways in various research applications. -
Anticancer Agent
(-)-Hinesol primarily functions as a potent anticancer agent. It induces apoptosis and causes cell cycle arrest at the G0/G1 phase. This compound downregulates the MEK/ERK and NF-κB signaling pathways, influencing the expression of key proteins such as cyclin D1, Bax, and Bcl-2. (-)-Hinesol shows significant potential for the research of non-small cell lung cancer. -
IRAK4 Inhibitor
Emavusertib hydrochloride is an orally active inhibitor targeting IRAK4, with an IC50 of 57 nM, and FLT3. This compound effectively inhibits NF-κB and MyD88 signaling pathways, resulting in decreased production of pro-inflammatory cytokines such as IL-6 and IL-10. Its anti-inflammatory and anti-proliferative properties make it a valuable tool for cancer research, as it promotes apoptosis in cancer cells and demonstrates antitumor efficacy in mouse model studies. -
HDAC1/2 and CDK2 Inhibitor
HDAC1/2 and CDK2-IN-1 is a dual inhibitor targeting HDAC1, HDAC2, and CDK2, with IC50 values of 70.7 μM, 23.1 μM, and 0.80 μM, respectively. This compound effectively disrupts the cell cycle and promotes apoptosis in tumor cells, demonstrating significant in vivo antitumor activity. It is suitable for research applications focused on cancer biology and therapeutic interventions targeting histone deacetylases and cyclin-dependent kinases. -
HDAC/MBLAC2 Inhibitor
Pracinostat dihydrochloride is a potent inhibitor of histone deacetylases (HDACs), demonstrating IC50 values in the range of 40-140 nM, making it a valuable tool in cancer research. In addition, it effectively inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) with an EC50 below 10 nM, highlighting its potential use in studies related to epigenetic regulation and resistance mechanisms in cancer therapies. -
Immunomodulator
Laquinimod sodium is a potent immunomodulator targeting neuroinflammation and neurodegeneration within the central nervous system. This orally available carboxamide derivative effectively reduces astrocytic NF-κB activation, offering protection against Cuprizone-induced demyelination. Laquinimod sodium is applicable in research focused on relapsing-remitting and chronic progressive forms of multiple sclerosis, as well as in studies of various neurodegenerative diseases. -
Cereblon Modulator
Avadomide hydrochloride is an oral cereblon modulator that targets cereblon E3 ligase activity. By inhibiting the NF-κB signaling pathway and arresting the cell cycle at the G1 phase, it effectively induces apoptosis in pancreatic ductal adenocarcinoma (PDAC) cells. This compound demonstrates significant antitumor and immunomodulatory properties, making it a valuable reagent for cancer research applications. -
Apoptosis Inducer
Apoptosis Inducer 46 targets apoptotic pathways to induce cell death selectively in metastatic triple-negative breast cancer (TNBC) cells. It demonstrates potent growth inhibitory effects, specifically causing G2/M phase cell cycle arrest and promoting apoptotic cell death in MDA-MB-231 cells. Additionally, Apoptosis Inducer 46 inhibits NF-κB nuclear translocation, highlighting its potential for research applications in the study of TNBC. -
HDAC Inhibitor
HDAC-IN-73 is a potent histone deacetylase (HDAC) inhibitor targeting HDAC1 and HDAC6, with IC50 values of 0.17 µM and 0.49 µM, respectively. Its enhanced activity against HDAC6 demonstrates a nine-fold greater potency compared to PsA, making it a valuable compound in the field of cancer research. HDAC-IN-73 exhibits significant antiproliferative effects, induces apoptosis, and triggers G2/M cell cycle arrest, positioning it as a promising candidate for investigating therapies in colon cancer and other malignancies. -
HDAC Inhibitor
HDAC-IN-96 is a selective inhibitor of histone deacetylases 1 and 2 (HDAC1/2), exhibiting IC50 values of 457.1 nM and 433.7 nM, respectively. This compound demonstrates significant cytotoxicity against various hematological tumor cell lines, including RS4;11, K562, RPMI-8226, and U266, with IC50 values between 2.11 and 5.35 μM. HDAC-IN-96 has been shown to induce apoptosis and cause S phase arrest in cancer cells, making it a valuable tool for research in hematological malignancies such as acute lymphoblastic leukemia. -
Aurora A/Aurora B/HDAC1/HDAC2 Inhibitor
Aurora kinase/HDAC-IN-1 is a potent dual inhibitor targeting Aurora A, Aurora B, HDAC1, and HDAC2. This compound promotes histone H3 acetylation, inhibits Aurora A phosphorylation and downstream signaling, and induces apoptosis through G2/M cell-cycle arrest. It demonstrates significant antiproliferative activity in colorectal cancer cells, with an IC50 of 30.2 nM in HCT-116 cells, and effectively suppresses tumor growth in HCT-116 colorectal cancer xenograft mouse models. This reagent is valuable for research in cancer biology and therapeutic application development. -
HDAC1/CDK7 Inhibitor
HDAC1/CDK7-IN-1 is a dual inhibitor targeting HDAC1 and CDK7, exhibiting IC50 values of 893 nM and 248 nM, respectively. This compound effectively inhibits the proliferation of cancer cell lines, including MDA-MB-231, MCF-7, A549, and HCT-116. Additionally, HDAC1/CDK7-IN-1 induces cell cycle arrest and apoptosis specifically in HCT-116 cells, while also disrupting their migratory capacity. These properties make it a valuable tool for cancer research, particularly in exploring therapeutic strategies that target epigenetic regulation and cell cycle dynamics. -
HDAC Inhibitor
WMJ-J-09 is a potent HDAC inhibitor with sub-nanomolar activity, exhibiting IC50 values of 7.5 nM against HDAC1 and 3.9 nM against HDAC6, along with notable activity towards HDAC2, HDAC3, and HDAC8. This compound effectively disrupts the cell cycle and promotes apoptosis in cancer cells through the LKB1-AMPK-p38MAPK-p63-survivin signaling pathway. By inhibiting HDAC enzyme activity, WMJ-J-09 leads to the acetylation of critical proteins, thus contributing to the regulation of cell death in cancer models, such as HCT116 and FaDu cells. -
HDAC Inhibitor
TH-6 is a potent inhibitor of histone deacetylases (HDACs), demonstrating IC50 values of 0.115 µM for HDAC1, 0.135 µM for HDAC2, 0.242 µM for HDAC3, 0.138 µM for HDAC6, and 2.120 µM for HDAC8. This compound effectively inhibits cell migration and invasion while promoting apoptosis and inducing cell cycle arrest in the G2/M phase. TH-6 exhibits significant anti-tumor activity, making it a valuable tool for cancer research and therapeutic studies. -
HDAC Inhibitor
HDAC-IN-36 is a potent HDAC (histone deacetylase) inhibitor that targets HDAC6 with an IC50 of 11.68 nM. This compound demonstrates significant biological activity by promoting apoptosis, enhancing autophagy, and inhibiting cellular migration. HDAC-IN-36 is applicable in cancer research, particularly in studies focusing on anti-tumor and anti-metastatic mechanisms in breast cancer. -
HDAC Inhibitor
Trichostatin C is an HDAC inhibitor that plays a crucial role in modulating gene expression by preventing the deacetylation of histones. This compound exhibits significant anticancer activity, inducing apoptosis and causing cell cycle arrest in the G2/M phase, making it particularly effective against lung cancer and urothelial bladder cancer. Additionally, Trichostatin C promotes differentiation in Friend leukemic cells and demonstrates antifungal properties, highlighting its potential in various research applications related to cancer biology and fungal infections. -
IKK/STAT3 Dual Inhibitor
ACHP is a selective IκB kinase (IKK) and STAT3 dual inhibitor, demonstrating potent inhibitory activity with IC50 values of 8.5 nM and 250 nM for IKKβ and IKKα, respectively. It effectively disrupts the STAT3 signaling pathway, leading to cancer cell cycle arrest and apoptosis. Additionally, ACHP exhibits significant anti-inflammatory properties in preclinical models, such as the mouse ear edema model. This compound is a valuable tool for research in anti-inflammatory and anti-cancer studies, including applications in multiple myeloma and leukemia. -
JMJD3/HDAC1/HDAC6 Inhibitor
JMJD3/HDAC-IN-1 is a dual inhibitor targeting both Jumonji domain-containing protein demethylase 3 (JMJD3) and histone deacetylases HDAC1 and HDAC6. With an IC50 value of 16 nM for HDAC1, this compound induces hypermethylation of histone H3K27 and hyperacetylation of H3K9, promoting apoptosis through cleavage of caspase-7 and PARP. JMJD3/HDAC-IN-1 demonstrates significant anti-cancer activity by inhibiting cell cloning, migration, and invasion, making it valuable in cancer research and therapeutic studies. -
Antioxidant
Astaxanthin is a potent antioxidant primarily targeting NF-κB, leading to the down-regulation of VEGF in blood glucose regulation. This carotenoid exhibits significant anti-cancer properties by inhibiting cell proliferation, enhancing apoptosis, and preventing migration and invasion through PPARγ activation and STAT3 expression reduction. Additionally, astaxanthin demonstrates neuroprotective and anti-inflammatory activities, making it applicable in various research fields, including cancer, diabetic retinopathy, and cardiovascular disease, as well as in the enhancement of animal feed coloration. -
Short-chain Fatty Acid
Sodium propionate is a short-chain fatty acid with multiple biological activities, primarily functioning as an oral bioactive compound. It enhances PPAR-γ activity while inhibiting NF-κB activation, leading to reduced COX-2 expression and nitric oxide production. Additionally, sodium propionate has demonstrated the ability to induce apoptosis and autophagy, exhibit anticancer effects against glioblastoma, and provide neuroprotective, antioxidant, and anti-inflammatory properties. This compound is suitable for research applications in areas such as spinal cord injury and Alzheimer's disease. -
TLR7/8 Antagonist
Afimetoran is a selective and highly bioavailable antagonist of Toll-like receptors 7 and 8 (TLR7/8). It effectively inhibits TLR7/8-mediated activation of the NF-κB signaling pathway and can reverse TLR7-induced resistance to steroid-driven apoptosis in plasmacytoid dendritic cells. This compound is particularly relevant for research into inflammation and autoimmune diseases, including systemic lupus erythematosus. -
HDAC3/p-STAT3 Inhibitor
1-Stearoyl-sn-glycero-3-phosphocholine is an inhibitor of histone deacetylase 3 (HDAC3) and the phosphorylation of signal transducer and activator of transcription 3 (p-STAT3). This compound has demonstrated the ability to induce apoptosis and exhibits significant anticancer activity in chronic myelogenous leukemia (CML) K562 cells. It serves as a valuable tool for researchers investigating the therapeutic potential of HDAC inhibitors in cancer treatment. -
Vascular Function Regulator
12-HETE is a significant metabolite of arachidonic acid produced via 12-lipoxygenase (12-LOX) catalysis, functioning as a vascular function regulator. It exhibits dose-dependent inhibition of cell apoptosis and promotes the activation and nuclear translocation of NF-κB through the integrin-linked kinase (ILK) pathway. Additionally, 12-HETE has been shown to possess both anti-thrombotic and pro-thrombotic effects, as well as neuromodulatory properties, making it valuable for research in vascular biology and related therapeutic areas. -
TRIP13 Inhibitor
DCZ0415 is a potent inhibitor of TRIP13, interfering with the nonhomologous end joining DNA repair mechanism and inhibiting NF-κB activity. This compound exhibits significant anti-myeloma activity in vitro, in vivo, and in primary cells obtained from drug-resistant myeloma patients, making it a valuable tool for research into therapeutic strategies against multiple myeloma. Its mechanism of action offers insights into the role of TRIP13 in cancer biology and the potential for targeted therapies. -
TLR2/4 Inhibitor
Robinin is a flavonoid that acts as an inhibitor of Toll-like receptors 2 and 4 (TLR2/4), modulating the TGF-β, TLR4/NF-κB, and TLR2-PI3k-AKT signaling pathways. This compound demonstrates significant anti-inflammatory and anti-tumor properties. Additionally, Robinin has been shown to enhance the anti-inflammatory effects of Methotrexate in experimental arthritis models and may mitigate cardiac toxicity induced by Doxorubicin. These attributes make Robinin a valuable reagent for research applications in inflammation and cancer therapy. -
Mucolytic Agent
Carbocisteine is an orally active mucolytic agent primarily targeting the modulation of mucous viscosity in respiratory conditions. It inhibits the phosphorylation of NF-κB p65 and ERK1/2, and further regulates the interplay between Nrf2/HO-1 and NF-κB pathways. Additionally, carbocisteine has demonstrated anti-apoptotic properties. This reagent is primarily utilized in research related to chronic obstructive pulmonary disease (COPD). -
ACE/IKK-β/PKC Inhibitor
Plantainoside D is a phenylethanoid glycoside that functions primarily as an inhibitor of IKK-β, with additional inhibitory effects on angiotensin-converting enzyme (ACE) and protein kinase C (PKC). It exhibits significant biological activities, including the reduction of glutamate release in the rat cerebral cortex, alleviating cell apoptosis through the inhibition of reactive oxygen species (ROS) and NF-κB activation. Additionally, Plantainoside D has been shown to improve outcomes in acute lung injury induced by sepsis via modulation of the Sirt3/NLRP3 signaling pathway. This compound is applicable in studies of neuroprotection, antioxidant activity, anti-inflammatory responses, and antihypertensive effects. -
TREM-1 Inhibitor
Nangibotide is a synthetic peptide that serves as a TREM-1 receptor inhibitor. By inhibiting NF-κB and NLRP3 inflammasome activation, Nangibotide effectively reduces the release of pro-inflammatory cytokines such as IL-1β and IL-8 and mitigates apoptosis. This reagent is valuable for research applications related to excessive inflammatory responses, including studies on myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure. Additionally, Nangibotide offers protective effects on tissues, such as the liver and lung, during inflammatory conditions. -
Bioactive Peptide
MOTS-c (human) is a bioactive peptide derived from mitochondria that modulates the AMPK/PGC-1α pathway, thereby enhancing insulin sensitivity. This peptide inhibits the folate cycle and de novo purine synthesis, elevating AICAR levels to activate AMPK, which regulates the Nrf2/Keap1 antioxidant pathway and suppresses the NF-κB inflammatory pathway. MOTS-c promotes mitochondrial biogenesis and energy metabolism, resulting in improvements in glucose and lipid metabolism, anti-oxidative stress, and neuroprotection. It is applicable in research studying type 2 diabetes, traumatic brain injury, inflammatory diseases, and age-related metabolic disorders. -
Prolyl-hydroxylase Inhibitor
Ethyl 3,4-dihydroxybenzoate is a competitive inhibitor of prolyl hydroxylase, effectively penetrating the blood-brain barrier. By inhibiting the hydroxylation of hypoxia-inducible factor (HIF), it stabilizes HIF-1α, thereby activating downstream pathways that promote autophagy and apoptosis in tumor cells. Additionally, it modulates inflammatory responses, inhibits the NF-κB pathway, enhances vascular permeability, and supports osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate is beneficial for research applications focused on cancer therapeutics, cardiovascular protection, bone metabolism regulation, and high-altitude cerebral edema management. -
Keap1-Nrf2 Protein-Protein Inhibitor
CPUY192018 is a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, exhibiting an IC50 of 0.63 µM. This compound demonstrates significant anti-inflammatory and antioxidant properties by activating the Nrf2-dependent pathway and inhibiting the NF-κB-related inflammatory response. CPUY192018 is ideal for research applications focused on inflammation-related diseases and the modulation of oxidative stress. -
Anticancer/Antiparasitic Agents
Bruceine A, a natural quassinoid, primarily targets NF-κB and PFKFB4, demonstrating a Kd of 44 nM. This compound exhibits potent anticancer and antiparasitic activities, effectively inhibiting cancer cell migration and inducing apoptosis while also disrupting the cell cycle. Bruceine A is a valuable research tool for studying pancreatic cancer, breast cancer, and parasitic infections. -
Anti-inflammatory agent
Hederacoside C is a potent anti-inflammatory agent that targets the MAPK/NF-κB signaling pathway. It exerts its biological activity by inhibiting the activation of this pathway, resulting in a reduction of inflammation. In addition to its anti-inflammatory properties, Hederacoside C also demonstrates antibacterial activity, making it a valuable compound for research applications focused on inflammatory diseases and infections.
